<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561128</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1819-I-101-AUS</org_study_id>
    <nct_id>NCT04561128</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1819 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered SHR-1819 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atridia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atridia Pty Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomized, double-blind, placebo-controlled, single dose escalation&#xD;
      phase 1 study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, randomized, double-blind, placebo-controlled, single dose escalation&#xD;
      phase 1 study. The objective of this study is to evaluate the safety, tolerability,&#xD;
      pharmacokinetics and pharmacodynamics of subcutaneous administered SHR-1819 in healthy&#xD;
      subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Start of Treatment to end of study (approximately 13 weeks)</time_frame>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-last</measure>
    <time_frame>Start of Treatment to end of study (approximately 13 weeks)</time_frame>
    <description>Area under the concentration-time curve from time 0 to last time point after SHR-1819 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-inf</measure>
    <time_frame>Start of Treatment to end of study (approximately 13 weeks)</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity after SHR-1819 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Tmax</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <description>Time to Cmax of SHR-1819</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Cmax</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <description>Maximum observed concentration of SHR-1819</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-CL/F</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <description>Apparent clearance of SHR-1819</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Vz/F</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <description>Apparent volume of distribution during terminal phase of SHR-1819</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-t1/2</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <description>Terminal elimination half-life of SHR-1819</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to end of treatment for TARC/CCL17</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <description>TARC/CCL17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to end of treatment for IgE</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <description>IgE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicy of SHR-1819 after administration</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <description>Anti-drug antibody</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>SHR-1819</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: SHR-1819</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator: placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1819</intervention_name>
    <description>SHR-1819 will be subcutaneously administered with different dose levels</description>
    <arm_group_label>SHR-1819</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be subcutaneously administered with different dose levels</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand the trial procedures and possible adverse events, volunteers to&#xD;
             participate in the trial, and provides written informed consent.&#xD;
&#xD;
          -  Be able to comply with all the requirements and able to complete the study.&#xD;
&#xD;
          -  Male or female aged between 18 years and 55 years (inclusive) at the date of signed&#xD;
             consent form.&#xD;
&#xD;
          -  No clinically significant abnormalities in medical history, general physical&#xD;
             examination, vital signs, and laboratory tests.&#xD;
&#xD;
          -  Men and women of childbearing potential (WOCBP) must agree to take effective&#xD;
             contraceptive methods and have no plan to have a child from signing the consent form&#xD;
             to 16 weeks after IP administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive hepatitis B virus (HBsAg), hepatitis C virus (HCV-Ab), human immunodeficiency&#xD;
             virus (HIV-Ab), or QuantiFERON-TB Gold tests at screening;&#xD;
&#xD;
          -  Participation in clinical trials of other investigational drugs or medical devices&#xD;
             within 3 months prior to screening (according to the date of signed consent form), or&#xD;
             in the follow-up period of a clinical study&#xD;
&#xD;
          -  Severe injuries or surgeries within 6 months before screening or plan to do surgeries&#xD;
             during the trial&#xD;
&#xD;
          -  Any other circumstances that, in the investigator's judgment, may increase the risk&#xD;
             associated with the subject's participation in and completion of the study or could&#xD;
             preclude the evaluation of the subject's response&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kathy You</last_name>
    <phone>+610192990433</phone>
    <email>kathyyou@atridia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atridia Pty Limited</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongqing You</last_name>
      <phone>61 426 422 488</phone>
      <email>kathyyou@atridia.com</email>
    </contact>
    <contact_backup>
      <last_name>Jessie Jiang, MD, Ph.D</last_name>
      <email>jiangxiuhong@shhrp.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

